[{"x_label":"Neuroblastoma  (Dataset = All Cohorts, Specimen = Pediatric Relapse Tumors, N = 14)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":14,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"All Cohorts","Disease":"Neuroblastoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000621","MONDO":"MONDO_0005072","GTEx_tissue_subgroup_UBERON":"","TPM_mean":2.79,"TPM_sd":2.51,"TPM_min":0.06,"TPM_25th_percentile":0.56,"TPM_median":2.57,"TPM_75th_percentile":4.18,"TPM_max":9.25},{"x_label":"Neuroblastoma  (Dataset = PBTA, Specimen = Pediatric Relapse Tumors, N = 6)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":6,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"PBTA","Disease":"Neuroblastoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000621","MONDO":"MONDO_0005072","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.44,"TPM_sd":1.4,"TPM_min":0.06,"TPM_25th_percentile":0.2,"TPM_median":1.37,"TPM_75th_percentile":2.28,"TPM_max":3.41},{"x_label":"Neuroblastoma  (Dataset = TARGET, Specimen = Pediatric Relapse Tumors, N = 8)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":8,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TARGET","Disease":"Neuroblastoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000621","MONDO":"MONDO_0005072","GTEx_tissue_subgroup_UBERON":"","TPM_mean":3.8,"TPM_sd":2.75,"TPM_min":0.41,"TPM_25th_percentile":2.31,"TPM_median":4.02,"TPM_75th_percentile":4.55,"TPM_max":9.25},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 13)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":13,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.65,"TPM_sd":0.83,"TPM_min":0.25,"TPM_25th_percentile":1.14,"TPM_median":1.31,"TPM_75th_percentile":2.37,"TPM_max":3.34},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 14)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":14,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.57,"TPM_sd":1.6,"TPM_min":0.29,"TPM_25th_percentile":0.61,"TPM_median":1.16,"TPM_75th_percentile":1.49,"TPM_max":5.78},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 5)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":5,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.46,"TPM_sd":1.11,"TPM_min":0.26,"TPM_25th_percentile":0.76,"TPM_median":1.34,"TPM_75th_percentile":1.75,"TPM_max":3.17},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 3)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":3,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.6,"TPM_sd":2.19,"TPM_min":3.29,"TPM_25th_percentile":3.33,"TPM_median":3.38,"TPM_75th_percentile":5.25,"TPM_max":7.12}]